Senate’s drug price hearing: 6 takeaways

(By Alia Paavola for Becker’s Hospital Review)

Seven pharmaceutical executives, representing $140 billion in U.S. revenue, testified before the Senate Finance Committee Feb. 26.

During the high-stakes hearing, lawmakers asked top executives to describe and defend their pricing strategies, what keeps them awake at night and their thoughts on various drug reform bills.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.